HomeEXECUTIVES
EXECUTIVES
The medical device news magazine is the latest source for industry scoop. In this article, we take a look at which executives are on the move.
As the medical device industry rapidly expands, so does the need for executive leadership. Recently, several top executives have made moves within the industry. Some have taken new positions at other companies, while others have started their own businesses. Here’s a look at who’s been making headlines lately.
Nima Farzan: New CEO at Latigo Biotherapeutics
Nima Farzan brings more than two decades' leadership experience with a strong track record in fundraising and IPOs.
Dasyo Welcomes Medical Aesthetics Industry Icon Domenic Serafino (Dom) as Executive Chair
Domenic Serafino was part of the start-up executive team at Syneron Medical Corp acting as its President of North America and Executive Vice President - Syneron Medical Israel. He was instrumental in helping Syneron IPO in 2004, reaching a market cap of $1.3 billion less than 18 months from IPO.
Clément Vidal Is Appointed New CEO at eCential
Under Clément Vidal's leadership, eCential Robotics will continue to build a culture of excellence, enhance the company's product portfolio roadmap, develop its commercial activities in the US as well as partner internationally with implant manufacturers, tech companies and research labs to expand the range of Applications available on its unique Open eCential Platform.
Chris McHugh Joins Zeus as Senior Vice President of Integrated Supply Chain
Chris McHugh has been named Senior Vice President of Integrated Supply Chain at Zeus and will be responsible for end-to-end operations across the company’s global network of manufacturing facilities
LeAnn Boyd Joins Presenters at Women Leaders in Healthcare Conference
Selected by Modern Healthcare as one of its Women Leaders for 2024, LeAnn Boyd is among an elite group of influential women working to improve the patient experience while advancing the objectives of their own organizations.
Josh Smale Appointed VP of Global Clinical and Scientific Affairs at R3 Vascular
Commenting on the appointment of Mr. Josh Smale, Christopher M. Ownes, President and CEO of R3 Vascular said, “On behalf of the R3 management team, I am very pleased to welcome Josh Smale as Vice President of Global Clinical and Scientific Affairs. Josh has a proven track record and more than 20 years of relevant medical device experience specializing in clinical and regulatory affairs strategy, clinical evidence generation and dissemination, and physician education. Among other key clinical and scientific affairs programs, Josh will lead our clinical trial efforts, including our pivotal ELITE trial for our next generation Magnitude drug eluting bioresorbable scaffold. We look forward to his contributions as we work towards establishing R3 Vascular as the leader in the development and manufacturing of fully bioresorbable vascular scaffolds.”
Long-time Collaborators Botond Roska and José-Alain Sahel Win the Wolf Prize 2024 in the Field of Medicine
The Wolf Prize, considered one of the most prestigious international awards, recognizes outstanding achievements in various fields including medicine.
LIfT BioSciences Appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors
Alex Blyth, Chief Executive Officer of LIfT BioSciences commented: “On behalf of LIfT’s Board of Directors, I am pleased to welcome Tony to the Company as Chairman. Tony has extremely relevant experience, having played a key role in successfully bringing three new drug modalities to the market, extensive experience in immuno-oncology, and has helped build several multi-billion-dollar companies from start-up stage. This wealth of experience will prove invaluable to LIfT as we prepare to move into clinical trials for our allogeneic first-in-class neutrophil-based immuno-cell therapy and other exciting pipeline developments.”
Ronil Patel Appointed Chief Business Officer at RevOpsis Therapeutics
Ronil Patel currently serves as a strategic advisor to Collage Venture Partners and was previously the Chief Business Officer at Ocuphire Pharma, a publicly traded ophthalmology biotechnology company. Prior to Ocuphire, Patel led business development for Point Guard Partners and Oculos Clinical Research (now iuvo Bioscience). Patel has been instrumental in biotech research and development and global business expansion. He has also contributed to teams that have secured approximately $100 million in funding and finalized licensing and exit deals valued at over $500 million.
